Isofol Medical AB (publ) (STO:ISOFOL)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.6870
-0.0130 (-1.86%)
Apr 10, 2026, 4:53 PM CET
Market Cap196.78M -28.3%
Revenue (ttm)n/a
Net Income-54.17M
EPS-0.25
Shares Out281.11M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume269,187
Average Volume699,659
Open0.7010
Previous Close0.7000
Day's Range0.6710 - 0.7190
52-Week Range0.5515 - 2.2940
Beta0.87
RSI57.41
Earnings DateMay 19, 2026

About Isofol Medical AB

Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol ISOFOL
Full Company Profile

Financial Performance

Financial Statements